Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 6/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208721 | 0.77 | MEN1 (0.39) | ARKDM4E | |
| SCHEMBL5435016 | 0.74 | ALDH1A1 (0.48) | KDM4EATM | |
| SCHEMBL22186737 | 0.72 | MAPT (0.40) | MAPTKDM4E | |
| SCHEMBL15306532 | 0.72 | PTGS1 (0.40) | MAPTKDM4EPDE4BATMDAO | |
| SCHEMBL10048365 | 0.71 | MAPT (0.62) | ARMAPTKDM4EPDE4APDE4B | |
| SCHEMBL3215294 | 0.71 | AKR1B1 (0.43) | ARKDM4E | |
| SCHEMBL8480598 | 0.70 | GRIN2D (0.45) | ARMAPTKDM4EPDE4BATM | |
| SCHEMBL756815 | 0.70 | DAO (0.51) | ARPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6547971 | 0.69 | GABRA1 (0.45) | ARKDM4EATM | |
| SCHEMBL21093803 | 0.69 | MAPT (0.35) | MAPTKDM4ECALCRLRETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041661-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-02-18 | — | — | US | disclosed |
| EP-2079710-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008056897-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041661-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | CASP1, CASP2, CASP5 | AR 3887/4885MAPT 944/4885KDM4E 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.